Drug Profile


Alternative Names: 6B1; Anti-TGF-beta-2 monoclonal antibody - Cambridge Antibody Technology; Anti-transforming-growth-factor-beta-2 monoclonal antibody - Cambridge Antibody Technology; CAT 152; Human anti-TGF-beta-2 monoclonal antibody - Cambridge Antibody Technology; TGF-beta-2 monoclonal antibody - Cambridge Antibody Technology; Trabio

Latest Information Update: 22 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cambridge Antibody Technology
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Transforming growth factor beta2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cataracts; Proliferative vitreoretinopathy; Scars

Most Recent Events

  • 27 Jun 2005 Discontinued - Phase-II for Proliferative vitreoretinopathy in United Kingdom (unspecified route)
  • 27 Jun 2005 Discontinued - Preclinical for Cataracts (unspecified route)
  • 23 Mar 2005 Discontinued - Phase-II/III for Scars prevention in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top